Naloxone Market by Type and Application - Global Industry Analysis & Forecast to 2027

Published On : November 2019 Pages : 134 Category: Pharma & Healthcare Report Code : HC117177

SEGMENTS & REGIONS:

  • Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa

Naloxone Market by Type (Spray Forms, Injectable Forms) Application (Opioid Overdose, Preventing Opioid Abuse, Others) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The naloxone market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Naloxone is an opioid antagonist medicine used to block the impacts of narcotic medications, especially inside the setting of drug overdoses which are quickly turning into a main cause of death around the world. Naloxone blocks the impacts of narcotic prescription, including outrageous sleepiness, slowed breathing, or loss of awareness. Naloxone is a medicine that is approved by the food and drug administration (FDA) to avert overdose by narcotics, such as morphine, heroin, and oxycodone.

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global naloxone market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • ADAPT Pharma
  • Amneal Pharmaceuticals
  • Mylan
  • kaleo
  • Amphastar Pharmaceuticals
  • West Ward Pharmaceuticals
  • Sandoz
  • Pfizer

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Naloxone Market, By Type, Estimates and Forecast, 2017-2027 ($Million)

o    Spray Forms

o    Injectable Forms

·         Naloxone Market, By Application, Estimates and Forecast, 2017-2027 ($Million)

o    Opioid Overdose

o    Preventing Opioid Abuse

o    Others

·         Naloxone Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)

o    ADAPT Pharma

o    Amneal Pharmaceuticals

o    Mylan

o    kaleo

o    Amphastar Pharmaceuticals

o    West Ward Pharmaceuticals

o    Sandoz

o    Pfizer

·         Naloxone Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Naloxone Market, By Country

o    U.S. Naloxone Market

o    Canada Naloxone Market

o    Mexico Naloxone Market

o    Europe

§  Europe Naloxone Market, By Country

o    Germany Naloxone Market

o    UK Naloxone Market

o    France Naloxone Market

o    Russia Naloxone Market

o    Italy Naloxone Market

o    Rest of Europe Naloxone Market

o    Asia-Pacific

§  Asia-Pacific Naloxone Market, By Country

o    China Naloxone Market

o    Japan Naloxone Market

o    South Korea Naloxone Market

o    India Naloxone Market

o    Southeast Asia Naloxone Market

o    Rest of Asia-Pacific Naloxone Market

o    South America

§  South America Naloxone Market

o    Brazil Naloxone Market

o    Argentina Naloxone Market

o    Columbia Naloxone Market

o    Rest of South America Naloxone Market

o    Middle East and Africa

§  Middle East and Africa Naloxone Market

o    Saudi Arabia Naloxone Market

o    UAE Naloxone Market

o    Egypt Naloxone Market

o    Nigeria Naloxone Market

o    South Africa Naloxone Market

o    Rest of MEA Naloxone Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Naloxone Market, By Type

5.1.     Introduction

5.2.     Global Naloxone Revenue and Market Share by Type (2017-2027)

5.2.1.  Global Naloxone Revenue and Revenue Share by Type (2017-2027)

5.3.     Spray Forms

5.3.1.  Global Spray Forms Revenue and Growth Rate (2017-2027)

5.4.     Injectable Forms

5.4.1.  Global Injectable Forms Revenue and Growth Rate (2017-2027)

6.       Naloxone Market, By Application

6.1.     Introduction

6.2.     Global Naloxone Revenue and Market Share by Application (2017-2027)

6.2.1.  Global Naloxone Revenue and Revenue Share by Application (2017-2027)

6.3.     Opioid Overdose

6.3.1.  Global Opioid Overdose Revenue and Growth Rate (2017-2027)

6.4.     Preventing Opioid Abuse

6.4.1.  Global Preventing Opioid Abuse Revenue and Growth Rate (2017-2027)

6.5.     Others

6.5.1.  Global Others Revenue and Growth Rate (2017-2027)

7.       Naloxone Market, By Region

7.1.     Introduction

7.2.     Global Naloxone Revenue and Market Share by Regions

7.2.1.  Global Naloxone Revenue by Regions (2017-2027)

7.3.     North America Naloxone by Countries

7.3.1.  North America Naloxone Revenue and Growth Rate (2017-2027)

7.3.2.  North America Naloxone Revenue (Million USD) by Countries (2017-2027)

7.3.3.  United States

7.3.3.1.  United States Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.4.  Canada

7.3.4.1.  Canada Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.5.  Mexico

7.3.5.1.  Mexico Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.     Europe Naloxone by Countries

7.4.1.  Europe Naloxone Revenue and Growth Rate (2017-2027)

7.4.2.  Europe Naloxone Revenue (Million USD) by Countries (2017-2027)

7.4.3.  Germany

7.4.3.1.  Germany Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.4.  France

7.4.4.1.  France Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.5.  UK

7.4.5.1.  UK Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.6.  Russia

7.4.6.1.  Russia Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.7.  Italy

7.4.7.1.  Italy Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.     Asia-Pacific Naloxone by Countries

7.5.1.  Asia-Pacific Naloxone Revenue and Growth Rate (2017-2027)

7.5.2.  Asia-Pacific Naloxone Revenue (Million USD) by Countries (2017-2027)

7.5.3.  China

7.5.3.1.  China Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.4.  Japan

7.5.4.1.  Japan Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.5.  Korea

7.5.5.1.  Korea Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.6.  India

7.5.6.1.  India Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.     South America Naloxone by Countries

7.6.1.  South America Naloxone Revenue and Growth Rate (2017-2027)

7.6.2.  South America Naloxone Revenue (Million USD) by Countries (2017-2027)

7.6.3.  Brazil

7.6.3.1.  Brazil Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.4.  Argentina

7.6.4.1.  Argentina Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.5.  Columbia

7.6.5.1.  Columbia Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.     Middle East and Africa Naloxone by Countries

7.7.1.  Middle East and Africa Naloxone Revenue and Growth Rate (2017-2027)

7.7.2.  Middle East and Africa Naloxone Revenue (Million USD) by Countries (2017-2027)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.5.  Egypt

7.7.5.1.  Egypt Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.7.  South Africa

7.7.7.1.  South Africa Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.8.  Turkey

7.7.8.1.  Turkey Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

8.       Company Profiles

8.1.     ADAPT Pharma

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     Amneal Pharmaceuticals

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     Mylan

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     kaleo

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     Amphastar Pharmaceuticals

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     West Ward Pharmaceuticals

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Sandoz

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     Pfizer

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

9.       Naloxone Market Forecast (2017-2027)

9.1.     Global Naloxone Revenue (Millions USD) and Growth Rate (2017-2027)

9.2.     Naloxone Market Forecast by Regions (2017-2027)

9.2.1.  North America Naloxone Market Forecast (2017-2027)

9.2.1.1.  United States Naloxone Market Forecast (2017-2027)

9.2.1.2.  Canada Naloxone Market Forecast (2017-2027)

9.2.1.3.  Mexico Naloxone Market Forecast (2017-2027)

9.2.2.  Europe Naloxone Market Forecast (2017-2027)

9.2.2.1.  Germany Naloxone Market Forecast (2017-2027)

9.2.2.2.  France Naloxone Market Forecast (2017-2027)

9.2.2.3.  UK Naloxone Market Forecast (2017-2027)

9.2.2.4.  Russia Naloxone Market Forecast (2017-2027)

9.2.2.5.  Italy Naloxone Market Forecast (2017-2027)

9.2.2.6.  Rest of Europe Naloxone Market Forecast (2017-2027)

9.2.3.  Asia-Pacific Naloxone Market Forecast (2017-2027)

9.2.3.1.  China Naloxone Market Forecast (2017-2027)

9.2.3.2.  Japan Naloxone Market Forecast (2017-2027)

9.2.3.3.  Korea Naloxone Market Forecast (2017-2027)

9.2.3.4.  India Naloxone Market Forecast (2017-2027)

9.2.3.5.  Southeast Asia Naloxone Market Forecast (2017-2027)

9.2.3.6.  Rest of Asia-Pacific Naloxone Market Forecast (2017-2027)

9.2.4.  South America Naloxone Market Forecast (2017-2027)

9.2.4.1.  Brazil Naloxone Market Forecast (2017-2027)

9.2.4.2.  Argentina Naloxone Market Forecast (2017-2027)

9.2.4.3.  Columbia Naloxone Market Forecast (2017-2027)

9.2.4.4.  Rest of South America Naloxone Market Forecast (2017-2027)

9.2.5.  Middle East and Africa Naloxone Market Forecast (2017-2027)

9.2.5.1.  Saudi Arabia Naloxone Market Forecast (2017-2027)

9.2.5.2.  United Arab Emirates Naloxone Market Forecast (2017-2027)

9.2.5.3.  Egypt Naloxone Market Forecast (2017-2027)

9.2.5.4.  Nigeria Naloxone Market Forecast (2017-2027)

9.2.5.5.  South Africa Naloxone Market Forecast (2017-2027)

9.2.5.6.  Turkey Naloxone Market Forecast (2017-2027)

9.2.5.7.  Rest of Middle East and Africa Naloxone Market Forecast (2017-2027)

9.3.     Naloxone Market Forecast by Type (2017-2027)

9.3.1.  Naloxone Forecast by Type (2017-2027)

9.3.2.  Naloxone Market Share Forecast by Type (2017-2027)

9.4.     Naloxone Market Forecast by Application (2017-2027)

9.4.1.  Naloxone Forecast by Application (2017-2027)

9.4.2.  Naloxone Market Share Forecast by Application (2017-2027)


List of Tables

List of Tables and Figures:

Figure United States Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Naloxone Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Naloxone Revenue and Revenue Share by Type (2017-2018)
Figure Global Spray Forms Revenue and Growth Rate (2017-2018)
Figure Global Injectable Forms Revenue and Growth Rate (2017-2018)
Table Global Naloxone Revenue and Revenue Share by Application (2017-2018)
Figure Global Opioid Overdose Revenue and Growth Rate (2017-2018)
Figure Global Preventing Opioid Abuse Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Naloxone Revenue by Regions (2017-2018)
Figure North America Naloxone Growth Rate (2017-2018)
Figure North America Naloxone Revenue and Growth Rate (2017-2018)
Figure North America Naloxone by Countries (2017-2018)
Figure North America Naloxone Revenue (Million USD) by Countries (2017-2018)
Figure United States Naloxone Growth Rate (2017-2018)
Figure United States Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Naloxone Growth Rate (2017-2018)
Figure Canada Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Naloxone Growth Rate (2017-2018)
Figure Mexico Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Naloxone Growth Rate (2017-2018)
Figure Europe Naloxone Revenue and Growth Rate (2017-2018)
Figure Europe Naloxone by Countries (2017-2018)
Figure Europe Naloxone Revenue (Million USD) by Countries (2017-2018)
Figure Germany Naloxone Growth Rate (2017-2018)
Figure Germany Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Naloxone Growth Rate (2017-2018)
Figure France Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Naloxone Growth Rate (2017-2018)
Figure UK Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Naloxone Growth Rate (2017-2018)
Figure Russia Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Naloxone Growth Rate (2017-2018)
Figure Italy Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Naloxone Growth Rate (2017-2018)
Figure Rest of Europe Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Naloxone Growth Rate (2017-2018)
Figure Asia-Pacific Naloxone Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Naloxone by Countries (2017-2018)
Figure Asia-Pacific Naloxone Revenue (Million USD) by Countries (2017-2018)
Figure China Naloxone Growth Rate (2017-2018)
Figure China Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Naloxone Growth Rate (2017-2018)
Figure Japan Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Naloxone Growth Rate (2017-2018)
Figure Korea Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Naloxone Growth Rate (2017-2018)
Figure India Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Naloxone Growth Rate (2017-2018)
Figure Southeast Asia Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Naloxone Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Naloxone Growth Rate (2017-2018)
Figure South America Naloxone Revenue and Growth Rate (2017-2018)
Figure South America Naloxone by Countries (2017-2018)
Figure South America Naloxone Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Naloxone Growth Rate (2017-2018)
Figure Brazil Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Naloxone Growth Rate (2017-2018)
Figure Argentina Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Naloxone Growth Rate (2017-2018)
Figure Columbia Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Naloxone Growth Rate (2017-2018)
Figure Rest of South America Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Naloxone Growth Rate (2017-2018)
Figure Middle East and Africa Naloxone Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Naloxone by Countries (2017-2018)
Figure Middle East and Africa Naloxone Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Naloxone Growth Rate (2017-2018)
Figure Saudi Arabia Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Naloxone Growth Rate (2017-2018)
Figure United Arab Emirates Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Naloxone Growth Rate (2017-2018)
Figure Egypt Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Naloxone Growth Rate (2017-2018)
Figure Nigeria Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Naloxone Growth Rate (2017-2018)
Figure South Africa Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Naloxone Growth Rate (2017-2018)
Figure Turkey Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Naloxone Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Naloxone Revenue (Millions USD) and Growth Rate (2017-2018)
Table ADAPT Pharma Naloxone Financial Overview
Table Amneal Pharmaceuticals Naloxone Financial Overview
Table Mylan Naloxone Financial Overview
Table kaleo Naloxone Financial Overview
Table Amphastar Pharmaceuticals Naloxone Financial Overview
Table West Ward Pharmaceuticals Naloxone Financial Overview
Table Sandoz Naloxone Financial Overview
Table Pfizer Naloxone Financial Overview
Figure Global Naloxone Revenue (Millions USD) and Growth Rate (2018-2025)
Table Naloxone Market Forecast by Regions (2018-2025)
Figure North America Naloxone Market Forecast (2018-2025)
Figure United States Naloxone Market Forecast (2018-2025)
Figure Canada Naloxone Market Forecast (2018-2025)
Figure Mexico Naloxone Market Forecast (2018-2025)
Figure Europe Naloxone Market Forecast (2018-2025)
Figure Germany Naloxone Market Forecast (2018-2025)
Figure France Naloxone Market Forecast (2018-2025)
Figure UK Naloxone Market Forecast (2018-2025)
Figure Russia Naloxone Market Forecast (2018-2025)
Figure Italy Naloxone Market Forecast (2018-2025)
Figure Rest of Europe Naloxone Market Forecast (2018-2025)
Figure Asia-Pacific Naloxone Market Forecast (2018-2025)
Figure China Naloxone Market Forecast (2018-2025)
Figure Japan Naloxone Market Forecast (2018-2025)
Figure Korea Naloxone Market Forecast (2018-2025)
Figure India Naloxone Market Forecast (2018-2025)
Figure Southeast Asia Naloxone Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Naloxone Market Forecast (2018-2025)
Figure South America Naloxone Market Forecast (2018-2025)
Figure Brazil Naloxone Market Forecast (2018-2025)
Figure Argentina Naloxone Market Forecast (2018-2025)
Figure Columbia Naloxone Market Forecast (2018-2025)
Figure Rest of South America Naloxone Market Forecast (2018-2025)
Figure Middle East and Africa Naloxone Market Forecast (2018-2025)
Figure Saudi Arabia Naloxone Market Forecast (2018-2025)
Figure United Arab Emirates Naloxone Market Forecast (2018-2025)
Figure Egypt Naloxone Market Forecast (2018-2025)
Figure Nigeria Naloxone Market Forecast (2018-2025)
Figure South Africa Naloxone Market Forecast (2018-2025)
Figure Turkey Naloxone Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Naloxone Market Forecast (2018-2025)
Figure Global Naloxone Forecast by Type (2018-2025)
Figure Global Naloxone Market Share Forecast by Type (2018-2025)
Figure Global Naloxone Forecast by Type (2018-2025)
Figure Global Naloxone Forecast by Application (2018-2025)
Figure Global Naloxone Market Share Forecast by Application (2018-2025)
Figure Global Naloxone Forecast by Application (2018-2025)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country